Clavis Pharma ASA has appointed Athos Gianella-Borradori, an onco-haematologist and drug developer, as its new chief medical officer. This follows the death from cancer on 10 June 2010 of its previous CMO, Bo Nilsson.
Dr Gianella-Borradori will be responsible for driving the clinical development of the company’s product for acute myeloid leukaemia, currently in Phase 3, and for its therapy for pancreatic cancer, in Phase 2. A medical doctor by training, Dr Gianella-Borradori has spent the past 20 years in industry where he has focused on translational research and on the clinical development of anti-cancer agents. During this period he has held managerial and senior clinical research and development roles at Novartis AG, Crucell NV, Bavarian Nordic GmbH, Cyclacel Ltd and recently, at Merck Serono SA.
Copyright 2010 Evernow Publishing Ltd